Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Futubull > Quotes > IBIO iBio Inc > Detailed Quotes

IBIO iBio Inc

Watchlist
0.265
-0.013-4.79%
Trading Session 06/30 15:22 ET
Giving away premium quotes worth 5000 HKD/year to unlock more data
Get NOW
High
0.288
Open
0.269
Turnover
292.85K
Low
0.262
Pre Close
0.278
Volume
1.08M
Market Cap
57.73M
P/E(TTM)
Loss
52wk High
1.475
Shares
218.17M
P/E(Static)
Loss
52wk Low
0.221
Float Cap
57.25M
Bid/Ask %
11.11%
Historical High
60.600
Shs Float
216.35M
Volume Ratio
0.17
Historical Low
0.050
Dividend TTM
--
Div Yield TTM
--
P/B
0.73
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.50%
Amplitude
9.32%
Avg Price
0.272
Lot Size
1
Float Cap
57.25M
Bid/Ask %
11.11%
Historical High
60.600
Shs Float
216.35M
Volume Ratio
0.17
Historical Low
0.050
Dividend TTM
--
P/B
0.73
Dividend LFY
--
Turnover Ratio
0.50%
Amplitude
9.32%
Avg Price
0.272
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.
CEO: Isett III, Thomas F.
Market: AMEX
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top